Back to results
US 12,338,269 B2Granted
IL-2 superagonists in combination with anti-PD-1 antibodies
AssigneeMedicenna Therapeutics Inc.
InventorsFahar Merchant, Shafique Fidai
Life of this patent
Estimating the term…
Abstract
Human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2Rβ receptor as compared to wild-type IL-2 for use in combination therapies with anti-PD-1 antibodies for the treatment of cancer. Also provided are pharmaceutical compositions that include such anti-PD-1 antibodies and the disclosed IL-2 muteins.
Claims10
A nucleic acid encoding a fusion protein, wherein the fusion protein comprises an IL-2 mutein comprising the amino acid sequence of SEQ ID NO:
- 9, linked to a heterologous polypeptide, wherein the nucleic acid is contained within a T cell.
Dependencies are inferred from the claim text.